^
Association details:
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer

Excerpt:
To determine whether clinical responses matched the pattern of sensitivity to EGFR TKIs that we observed in vitro, we assembled data from 19 NSCLC patients with diverse EGFR exon 20 insertion mutations who were treated with reversible EGFR TKIs (Fig. 2A, 2B, Sup. Table 3)....almost all 19 NSCLC patients from our centers displayed progressive disease (PD) in the course of treatment with gefitinib or erlotinib (Fig. 2B, Sup. Table 3, and Sup. Fig. 5).
DOI:
10.1126/scitranslmed.3007205